Eric Gonzalez

Eric Gonzalez is a Senior Research Associate at Kimia Therapeutics since January 2024, previously serving in the same role at Eikon Therapeutics from June 2020 to October 2023. At Eikon Therapeutics, Eric developed, automated, and optimized cell line engineering processes involving point mutations, knockouts, and endogenous fluorescent protein knockins utilizing CRISPR/Cas9 technology. Eric's academic background includes a Master of Science in Biomedical Sciences with a focus on Stem Cell Science from San Francisco State University, as well as a Bachelor of Science in Cell/Cellular and Molecular Biology and Microbiology from California Polytechnic State University-San Luis Obispo. Prior experience includes research positions at the University of California, Berkeley, and California Polytechnic State University, alongside roles in personal care and customer service.